MYRIAD GENETICS INC
MYGN · In Vitro and in Vivo Diagnostic Substances
Latest available SEC filing: 4 ·
Latest disclosures
-
Wheeler Benjamin Richard: Form 4
Insider disclosure · Filed · Report period 21 Sep 2026
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 3
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Latest financial period: Q2 2026
Financial facts · Filed
Institutional holders by security
Choose a share class to see reported 13F positions and quarterly changes. Different securities have separate holder histories.
- MYGN · 62855J104 - Common Stock
Company details and SEC sources
CIK 0000899923 · SEC filing index. Filing dates describe disclosures, not live market data.
- Listed symbols
- MYGN on Nasdaq
- SEC industry group
- In Vitro and in Vivo Diagnostic Substances (Office of Life Sciences)
- Business address
- 322 North 2200 West, Salt Lake City, UT, 84116
- Incorporated in
- DE
- Fiscal year end
- 31 December
At a glance
Names, identifiers, and filing context for this profile.
2 identity fields